26.  Plaintiff brings this action pursuant to Federal Rule of Civil Procedure 23,  individually and on behalf of the stockholders of Livongo common stock who are being and will  be harmed by Defendants’ actions described herein (the “Class”).  The Class specifically excludes  Defendants herein, and any person, firm, trust, corporation or other entity related to, or affiliated  with, any of the Defendants.   34.  Livongo provides an integrated suite of solutions for the healthcare industry in  North America. The Company solutions promote health behavior change based on real-time data  capture supported by intuitive devices and insights driven by data science. The Company offers a  platform that provides cellular-connected devices, supplies, informed coaching, data science- enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes,  Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for  Behavioral Health by myStrength. The Company was formerly known as EosHealth, Inc. and  changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008  and is headquartered in Mountain View, California.   35.  The Company has shown steady financial success evidenced by its stock  performance and financial data. In fact, as recently as August 4, 2020, the day before the  announcement, Livongo’s stock price was as high as $150.00 per share, approximately $20 more per  share than the consideration in the Proposed Transaction.   36.  The Company’s most recent pre-announcement 10-Q indicated sustained and solid  financial performance.  For example, in a May 6, 2020 press release announcing its Fiscal 2020  Q1 financial results, Defendant Burke promoted the Company’s positive financial results,  “Livongo is well positioned to provide assistance to some of the most vulnerable populations  during the COVID-19 pandemic - people with chronic conditions - and our remote monitoring,  digitally powered and real-time personal coaching capabilities, and access to telehealth services  are well suited to track vital signs of interest in maintaining the health of our Members.”   37.  Defendant Burke went on to comment on a strong future outlook for Livongo, “We  are pleased to announce our relationship with the Government Employees Health Association, Inc.  (GEHA), to provide the Livongo for Diabetes, Hypertension, and Diabetes Prevention solutions  for federal employees, retirees, and their dependents that receive GEHA medical coverage.”   Aiding and Abetting the Board’s Breaches of Fiduciary Duty  (Against Livongo, Teladoc, and Merger Sub)  120.  Plaintiff incorporates each and every allegation set forth above as if fully set forth  herein.  121.  Defendants Livongo, Teladoc, and Merger Sub all knowingly assisted the  Individual Defendants’ breaches of fiduciary duty in connection with the Proposed Transaction,  which, without such aid, would not have occurred.  122.  As a result of this conduct, Plaintiff and the other members of the Class have been  and will be damaged in that they have been and will be prevented from obtaining a fair price for  their shares.  123.  Plaintiff and the members of the Class have no adequate remedy at law.  Company Background   